anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sclerostin inhibitors protect against osteoporotic fractures, but their cardiovascular safety remains unclear. We conducted a cis-Mendelian randomisation analysis to estimate the causal effect of sclerostin levels on cardiovascular risk factors. We meta-analysed three GWAS of sclerostin levels including 49,568 Europeans and selected 2 SNPs to be used as instruments. We included heel bone mineral density and hip fracture risk as positive control outcomes. Public GWAS and UK Biobank patient-level data were used for the study outcomes, which include cardiovascular events, risk factors, and biomarkers. Lower sclerostin levels were associated with higher bone mineral density and 85% reduction in hip fracture risk. However, genetically predicted lower sclerostin levels led to 25-85% excess coronary artery disease risk, 40% to 60% increased risk of type 2 diabetes, and worse cardiovascular biomarkers values, including higher triglycerides, and decreased HDL cholesterol levels. Results also suggest a potential (but borderline) association with increased risk of myocardial infarction. Our study provides genetic evidence of a causal relationship between reduced levels of sclerostin and improved bone health and fracture protection, but increased risk of cardiovascular events and risk factors.
Participants received placebo for bemarituzumab administered every 2 weeks with a single additional placebo dose on cycle 1 day 8. Participants also received mFOLFOX6 chemotherapy administered Q2W. Treatment continued until unacceptable toxicity, disease progression, or death.
An inhibitor preventing penetration of the cell membrane is produced as follows: A reactant, which consists of a spermatozoon or the SP-10 molecule, known in itself, found at the end of a spermatozoon, and/or of protein PH-20 or equivalent, such as a synthetically produced substance, is brought into contact with a second reactant, which is a substance found on the surface of the ovum and/or involved in the zona reaction of the ovum or an equivalent substance, such as a synthetically produced substance, the combination of said reactants leading to the formation of a substance inhibiting penetration of the cell membrane. The inhibitor preventing penetration of the cell membrane may be implemented as a contraceptive preventing fertilization, such as a contraceptive liquid for temporary use and/or a contraceptive vaccine and/or a contraceptive pill, e.g. for use by men as well as women. It may contain an antibody of the SP-10 molecule and an antibody of the PH-20 protein and guanosine triphosphate. An inhibitor preventing penetration of the cell membrane of red blood cells and blood platelet cells may be implemented as a liquid or equivalent, e.g. as a pill, for use as a thrombosis vaccine and/or medicine. An inhibitor preventing penetration of the cell membrane of white blood cells may be implemented as a liquid or equivalent, e.g. a pill, for use as an AIDS vaccine or medicine. The above-mentioned inhibitor, vaccines and medicines can be studied and developed e.g. by means of a blood-semen pretesting device.
Tiotropium 18 μg capsules for inhalation delivered once daily via HandiHaler® device for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
Systems and methods are disclosed that employ an indirect exclusionary approach to the identification of abnormal tissue regions based on the processing of a plurality of multimodal and/or multiparametric image datasets having respective parameters defining a parameter space. A region of parameter space associated with normal tissue, optionally determined in a subject-specific manner, is employed to facilitate the indirect detection and identification of voxels and/or regions associated with abnormal tissue. In some example embodiments, additional parameter space criteria may be employed to further limit the voxels associated with abnormal tissue. A physical space image showing locations of abnormal tissue voxels, or segmented regions associated therewith, may be presented and optionally dynamically updated as additional parameter space criteria is varied in response to user input. Abnormal tissue voxels may be detected locally or throughout an organ. Segmented regions may be employed for the training of a machine learning algorithm.
A surgical support system, a surgical support method, and an information storage medium are provided, which can support information so that a surgical team, surgical equipment, and the like can be managed in consideration of the real-time status of a surgery. The surgical support system (50) includes a processor (111) and a memory device (112). The processor (111) displays a surgical schedule screen representing a surgical schedule on the monitor (150). A storage device (112) stores operation content information relating to operation content, operation room information relating to an operation room, and operation time information relating to a scheduled operation time in association with an operation scheduled in an operation schedule. A processor (111) receives real-time surgical information, which is information relating to a real-time surgical condition, from an operating room. The processor (111) performs processing for displaying on a monitor (150) a surgical schedule screen in which real-time surgical information and a surgical procedure scheduled in a surgical schedule are associated with each other.
A computing system may generate an initial segmentation mask by applying a neural network to a 3D image of a set of objects. The initial segmentation mask associates voxels of the 3D image with individual objects of the set of objects. Additionally, the computing system generates a refined segmentation mask. As part of generating the refined segmentation mask, the computing system performs, for each respective object, a front propagation process for the respective object. The front propagation process for the respective object uses input voxel data to relabel, in the refined segmentation mask, voxels of the 3D image as being associated with the respective object. A stopping condition of a path evaluated by the front propagation process for the respective object occurs when the front propagation process evaluates a voxel identified in the initial segmentation mask as being associated with a different one of the objects from the respective object.
How the brain restores baseline consciousness at the end of a perioperative anesthetic is not known. However, it is becoming increasingly evident that arousal after sleep, coma, or anesthesia is an active process, not a passive process relying on simple clearance of anesthetic drugs. Insight into the specific sequence of brain circuit activation and inactivation during the end of an anesthetic may not only lead to an understanding of anesthetic emergence but provide important information for the potential long-term consequences of anesthetic drugs (anesthetic neurotoxicity, and the role of anesthetic drugs in delirium and dementia). The possibility of anesthesia causing harm to the brains of our patients is a controversy that has received a lot of attention from anesthesiologists, surgeons, and patients alike. The investigators' approach is to determine if techniques based on eye movements and/or pupillometry can predict and guide the post anesthesia management of delirium.

The conventional pupillary exam involves assessment of pupil size, shape, symmetry, and reactivity to light. Mechanistically, the pupillary light reflex involves the retina, cranial nerve II and III, pretectal nucleus in the midbrain, Edinger-Westphal nuclei, and the ciliary ganglion. With the use of an automated pupillometer, the pupillary response to light can also be quantified with measures of maximal diameter, latency, constriction velocity, minimal diameter, and dilation velocity. Beyond the reliability and accuracy that the device affords, pupillometry may have other utilities, potentially predicting postoperative delirium, episodes of intracranial hypertension, and even supratentorial herniation.

On the other hand, smooth pursuit involves conjugate eye movements that are required to maintain an object in motion on the fovea. The mechanism is quite complex, involving the lateral geniculate nucleus, primary visual cortex, middle temporal visual cortex, frontal pursuit area, superior colliculus, several pontine nuclei, the cerebellum, and nuclei of cranial nerves III, IV, and VI. It should not be surprising that cortical atrophy that occurs with normal aging or a dementing process may alter eye movements. The utility and relationship of pupillometry and Neurotrack™, alone and in combination with intraoperative electroencephalogram (EEG), is of immense interest. Prediction of post-operative delirium and cognitive decline with simple non-invasive means would be a significant clinical advancement.
The present invention relates to externally applied ointment which is traditional Chinese medicine ointment and is mainly prepared from the following major ingredients by weight parts. The externally applied ointment is prepared from 1 to 3 shares of musk, 2 to 4 shares of borneol, 2 to 7 shares of hairy deer-horn, 3 to 7 shares of Chinese caterpillar fungus, 2 to 4 shares of epimedium herb, 2 to 4 shares of notoginseng, 3 to 7 shares of prepared rhizome of rehmannia, 2 to 7 shares of common yan rhizome, 3 to 7 shares of cornus, 2 to 6 shares of eucommia bark, 2 to 7 shares of tremolite or tremolite asbestos, 2 to 7 shares of double blossom, 2 to 7 shares of phellodendron bark, 2 to 4 shares of cortex moutan root-bark of tree peony, 2 to 6 shares of edible tulip, 2 to 7 shares of tuckahoe and 2 to 7 shares of alpine snow lotus. The present invention has the following preparation method: the medicines are pulverized into fine powder of 180 meshes, and then, an amount of vaseline or glycerol is prepared to be a paste shape for standby. The present invention has the following medicine application method: the externally applied ointment is coated to fingers, and the medicine is uniformly coated to rectal mucosas by the digital examination of anuses. The present invention has the advantages of double efficiency on therapy and health care; the medicine application method is scientific and easy; the present invention is absorbed by tunica mucosa recti without the stimulation on the stomach and the intestine and toxic or side effects. The present invention has obvious clinic effects on treating hyperplasia of prostate, sexual impotence, coronary heart diseases and urinary infection, and the effective rate can be more than 92%.
Aim. Chronic kidney disease (CKD) and diabetes mellitus (DM) contribute significantly to cardiovascular disease (CVD) and mortality, with prevalence increasing. The evolving demographic of myocardial infarction (MI) patients, influenced by sedentary lifestyles and advanced medical care, lacks understanding regarding the interplay of CKD, DM, age, and post-MI mortality. This study aims to address this gap by evaluating the long-term impact of CKD and DM on post-MI mortality across age groups. Methods. A retrospective cohort study utilized data from the Estonian Myocardial Infarction Registry (EMIR), Estonian Population Register (EPR), and six major hospitals in Estonia, covering AMI hospitalizations from 2012 to 2019. Statistical analyses included Cox proportional hazards regression models and Kaplan-Meier's curves. Results. Analysis of 17,085 MI patients revealed age-dependent associations between renal function and mortality. In patients <65 years, even minor decreases in renal function increased both short-term (HR 2.79, 95% CI 1.71-4.55) and long-term (HR 1.24, 95% CI 1.05-1.47) mortality. Mortality significantly increased in patients >80 years only below an estimated glomerular filtration rate (eGFR) of 44 ml/min/1.73 m2. Newly diagnosed DM patients exhibited higher mortality rates (average HR 1.53, 95% CI 1.45-1.62), while pre-DM did not significantly differ from non-DM patients across all age groups. The DM-renal failure interaction did not significantly influence mortality. Conclusions. An age-dependent association between eGFR and post-MI outcomes emphasizes the need for personalized therapeutic approaches considering age-specific eGFR thresholds and comorbidities to optimize patient management.
A solid lyophilized taxane (preferably docetaxel and paclitaxel) composition, suitable for preparing pharmaceutical formulations for mammals, particularly humans, which comprises said taxane, a surface-active agent, a lyophilization excipient and an acid. Also, in addition, it is essentially free of organic solvent. Said solid composition is free of polysorbate 80 and of polyoxyethylated castor oil. It is sterile. It is soluble in aqueous solutions in the absence of organic solvent. Also, it has an apparent density of between 0.05 g/ml and 0.45 g/ml. A double lyophilization method for obtaining said solid taxane composition. A pharmaceutical formulation of a taxane that comprises said solid lyophilized taxane composition and a solubilizing composition. A kit that comprises said compositions and a syringe.
Fenofibrate, USP (micronized), is a lipid regulating agent available as capsules for oral administration. Each capsule contains 67 mg, 134 mg or 200 mg of micronized fenofibrate, USP. The chemical name for fenofibrate, USP is 2-[4-(4- chlorobenzoyl) phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester with the following structural formula:

The empirical formula is C20H21O4Cl and the molecular weight is 360.83; fenofibrate, USP is very soluble in methylene chloride; slightly soluble in alcohol; practically insoluble in water. The melting point is 79° to 82°C. Fenofibrate, USP is a white or almost white crystalline powder which is stable under ordinary conditions.

Each 67 mg fenofibrate capsule, USP (micronized) contains the following inactive ingredients: sodium lauryl sulfate, croscarmellose sodium, pregelatinized starch, microcrystalline cellulose, colloidal silicon dioxide, sodium stearyl fumarate, titanium dioxide and gelatin. The capsule shell imprinting ink contains the following inactive ingredients: shellac, black iron oxide and potassium hydroxide.

Each 134 mg fenofibrate capsule, USP (micronized) contains the following inactive ingredients: sodium lauryl sulfate, croscarmellose sodium, pregelatinized starch, microcrystalline cellulose, colloidal silicon dioxide, sodium stearyl fumarate, titanium dioxide, FD&C Yellow 6, D&C Yellow 10 and gelatin. The capsule shell imprinting ink contains the following inactive ingredients: shellac, black iron oxide and potassium hydroxide.

Each 200 mg fenofibrate capsule, USP (micronized) contains the following inactive ingredients: sodium lauryl sulfate, croscarmellose sodium, pregelatinized starch, microcrystalline cellulose, colloidal silicon dioxide, sodium stearyl fumarate, titanium dioxide, FD&C Yellow 6, D&C Yellow 10 and gelatin. The capsule shell imprinting ink contains the following inactive ingredients: shellac, black iron oxide and potassium hydroxide.
Liver haemangiomas are the most common benign hepatic tumours, but secondary portal hypertension resulting from haemangiomas is exceedingly uncommon. We present a case of a man in his 50s who presented with a progressively enlarging mass in the right upper abdomen. CT of the liver revealed a large hypodense lesion involving the right lobe, with two smaller lesions in the left lobe. The portal vein was compressed by the tumour, causing portal hypertension. The patient underwent right hepatectomy. Postoperatively, the patient had an uneventful course, and a 3-month follow-up demonstrated resolution of the oesophageal varices, portal gastropathy, with hypertrophy of the left lobe. This case report highlights the successful surgical management of a rare massive hepatic haemangioma causing portal hypertension with surgical resection, emphasising the potential benefits of surgical intervention with minimal complications.
Glucocorticoid (GC) therapy had been strongly recommended for pediatric sepsis (grade 1A). However, the recommendation was changed to grade 2C in 2020 due to weak evidence. About 32.8% of patients with pediatric septic develop relative adrenal insufficiency (RAI). But whether GC therapy should be determined by RAI status is controversial. This study utilized 21-day-old SF1CreSRBIfl/fl mice as the first pediatric RAI mouse model to assess the pathogenesis of RAI and evaluate GC therapy. RAI mice exhibited a substantially higher mortality rate in cecal ligation and puncture and cecal slurry-induced sepsis. These mice featured persistent inflammatory responses and were effectively rescued by GC therapy. RNA sequencing analysis revealed persistent inflammatory responses in RAI mice, caused by transcriptional dysregulation of AP-1 and NF-κB, and cytokine-induced secondary inflammatory response. Our findings support a precision medicine approach to guide GC therapy for pediatric patients based on the status of RAI.
All patients will be informed about the study before the gastroenterological procedure and the consent form will be signed by the patients who want to participate in the study. Demographic data of patients (age, weight, height), ASA (American Society of Anesthesiologists) classification, allergies, comorbidities (hypertension, coronary artery disease, chronic kidney disease, COPD), Mallampati scores, history of covid, history of covid vaccine, and history of previous anesthesia will be questioned and recorded before the gastroenterological procedure. Afterward, participants will be taken to the gastroenterology intervention room and standard monitorisation (Electrocardiogram, noninvasive blood pressure, peripheral oxygen saturation, and end-tidal CO2) will be performed. The measurements will be repeated every 5 minutes following the induction of anesthesia and recorded. Administered anesthetics and their doses at the induction and maintenance of sedation will be recorded. The person recording the data will not be the patient's primary anesthesiologist. The data will be recorded by a second anesthesiologist who will not interfere with the medical treatment and management of the patient. The presence of perioperative and postoperative complications (such as hypotension, hypertension, bradycardia, apnea, hypoxia, agitation, postoperative nausea and vomiting) will be observed by the second anesthesiologist and recorded. Hypertension is defined as an elevation in blood pressure more than 20% compared to perioperative values. Hypotension is defined as degradation in blood pressure more than 20% compared to perioperative values. Bradycardia is defined as less than 50 heartbeats per minute. Peripheral oxygen saturation below 90 will be referred to as hypoxia. Apnea is defined as "no respiratory effort for more than 20 seconds" or "a halt of breathing for more than 10 seconds. There will be no intervention for the patients. Patients will not be divided into groups or randomized. The data will be recorded by an impartial observer.
PURPOSE OF REVIEW: Obesity is a growing global health threat that significantly contributes to the burden of asthma by increasing the risk of developing asthma and exerting a distinct effect on lung function and inflammation. The treatment of obesity-related asthma is hindered by a poor response to standard asthma treatments, leading to worse asthma control. Weight loss strategies have a significant effect on asthma symptoms but are not feasible for a large proportion of patients, underscoring the need for a better understanding of the pathophysiology and the development of additional treatment options.
RECENT FINDINGS: Recent literature focusing on pathophysiology particularly delved into nontype 2 inflammatory mechanisms, associations with the metabolic syndrome and small airway impairment. Additionally, several new treatment options are currently investigated, including biologics, weight reduction interventions, and novel antiobesity drugs.
SUMMARY: Obesity-related asthma is a highly prevalent asthma phenotype for which weight loss strategies currently stand as the most specific treatment. Furthermore, novel pharmacological interventions aiming at metabolic processes are on the way.
Use of A-ring aromatized acetyl minocycline compounds (I) for treating T cell-mediated diseases, is claimed. Use of A-ring aromatized acetyl minocycline compounds of formula (I) for treating T cell-mediated diseases, is claimed. R1-R5 : acetyl or H, where at least one of R1-R5 is acetyl. An independent claimS included for a pharmaceutical composition comprising A-ring aromatized acetyl minocycline compounds (I) and a pharmaceutical acceptable carrier. [Image] ACTIVITY : Antiallergic; Immunosuppressive. Test details are described but no results for the compounds of the claims are given. MECHANISM OF ACTION : None given.
General: There is a possibility of increased absorption through ulcerated or inflamed skin.

Information for Patients: Patients should be forewarned that the reaction in the treated areas may be unsightly during therapy and, usually, for several weeks following cessation of therapy. Patients should be instructed to avoid exposure to ultraviolet rays during and immediately following treatment with EFUDEX because the intensity of the reaction may be increased. If EFUDEX is applied with the fingers, the hands should be washed immediately afterward. EFUDEX should not be applied on the eyelids or directly into the eyes, nose, or mouth because irritation may occur.

Fluorouracil, including EFUDEX may be fatal if ingested by pets. Avoid allowing pets to contact the EFUDEX container or the skin where EFUDEX has been applied. Store EFUDEX out of reach of pets. Safely discard or clean any cloth or applicator that may retain EFUDEX and avoid leaving any residues of EFUDEX on your hands, clothing, carpeting or furniture.
Disclosed embodiments include computer-implemented methods and systems that can efficiently generate highly relevant recommended search terms to clinicians. A hybrid collaborative filtering model recommends search terms for a specific patient to the clinician. The model draws on information from patients' clinical encounters and the searches that were performed during the clinical encounters. To generate recommendations, the model uses search terms which are (1) frequently co-occurring with the ICD codes recorded for the patient and (2) highly relevant to the most recent search terms. One variation of the model uses only the most recent ICD codes assigned to the patient. Another variation uses all ICD codes. Comprehensive experiments of embodiments of the methods and systems have demonstrate high levels of performance.
Investigators will include in our study patients aged 60 and over who have been evaluated in the pre-anesthesia clinic for procedures such as endoscopy, colonoscopy, ERCP, PEG, EUS, and ESD, and who have received sedation by an anesthesiologist. Patients will be assessed for frailty prior to the procedure; during and after the procedure, respiratory monitoring (SpO2, capnography) will be closely observed, and they will be contacted by phone three days later.